Recent reports from the Ice3 trial [56,57] involving 194 subjects, with a mean age of 74.9 years and hormone receptor-positive, HER2/neu-negative invasive breast cancer < 1.5 cm (range: 2.5–14.9 mm; mean diameter 8.1 mm), showed an only 2.1% ipsilateral breast tumor recurrence rate at 3 years [56] and 4.3% at 5 years [57]. This evidence concerns the gene ERBB2 and breast neoplasm.